Galena Biopharma Company Profile (NASDAQ:GALE)

About Galena Biopharma (NASDAQ:GALE)

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GALE
  • CUSIP: N/A
  • Web:
  • Market Cap: $13.48 million
  • Outstanding Shares: 38,405,000
Average Prices:
  • 50 Day Moving Avg: $0.38
  • 200 Day Moving Avg: $0.53
  • 52 Week Range: $0.16 - $4.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.42
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.51 per share
  • Price / Book: 0.69
  • EBIDTA: ($23,480,000.00)
  • Return on Equity: -76.75%
  • Return on Assets: -28.16%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.94%
  • Average Volume: 630,652 shs.
  • Beta: 1.83
  • Short Ratio: 8.58

Frequently Asked Questions for Galena Biopharma (NASDAQ:GALE)

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the NASDAQ under the ticker symbol "GALE."

How were Galena Biopharma's earnings last quarter?

Galena Biopharma, Inc. (NASDAQ:GALE) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. During the same period last year, the company earned $0.05 EPS. View Galena Biopharma's Earnings History.

Where is Galena Biopharma's stock going? Where will Galena Biopharma's stock price be in 2017?

2 analysts have issued 12 month price targets for Galena Biopharma's stock. Their predictions range from $4.00 to $4.00. On average, they expect Galena Biopharma's share price to reach $4.00 in the next twelve months. View Analyst Ratings for Galena Biopharma.

What are analysts saying about Galena Biopharma stock?

Here are some recent quotes from research analysts about Galena Biopharma stock:

  • 1. According to Zacks Investment Research, "Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon. " (5/16/2017)
  • 2. FBR & Co analysts commented, "On January 31, Galena Biopharma announced that Mark W. Schwartz, Ph.D., resigned as the company's president, CEO, and member of the board of directors, effective immediately. An interim CEO, who will oversee Galena as it explores strategic alternatives with assistance from an independent advisory firm, is expected to be appointed in the next several weeks. At this point, it is not certain whether Galena will continue clinical development of its pipeline on its own, outlicense its assets, or undergo restructuring of its corporate operations before a final decision is made in 2H17. We believe the high value of Galena's pipeline assets remains under-appreciated; however, due to near-term uncertainty, we are moving to the sidelines and lowering our rating from Outperform to Market Perform with a new price target of $4 versus our previous $11 price target." (2/6/2017)

Who are some of Galena Biopharma's key competitors?

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:

  • Sanford J. Hillsberg J.D., Chairman of the Board
  • Stephen F. Ghiglieri, Interim Chief Executive Officer, Executive Vice President, Principal Accounting Officer
  • Thomas J. Knapp, Interim General Counsel, Corporate Secretary
  • William L. Ashton, Independent Director
  • Richard H. Chin M.D., Independent Director
  • Irving M. Einhorn, Independent Director
  • Stephen S. Galliker CPA, Independent Director
  • Mary Ann Gray Ph.D., Independent Director

Who owns Galena Biopharma stock?

Galena Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.56%) and Virtu KCG Holdings LLC (0.60%). Company insiders that own Galena Biopharma stock include Hudson Bay Capital Management and Rudolph Nisi. View Institutional Ownership Trends for Galena Biopharma.

Who bought Galena Biopharma stock? Who is buying Galena Biopharma stock?

Galena Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Vanguard Group Inc.. View Insider Buying and Selling for Galena Biopharma.

How do I buy Galena Biopharma stock?

Shares of Galena Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of Galena Biopharma stock can currently be purchased for approximately $0.35.

MarketBeat Community Rating for Galena Biopharma (NASDAQ GALE)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galena Biopharma (NASDAQ:GALE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.00 (1,030.26% upside)

Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Maxim GroupReiterated RatingHoldHighView Rating Details
2/6/2017FBR & CoDowngradeOutperform -> Market Perform$11.00 -> $4.00N/AView Rating Details
9/20/2016S&P Equity ResearchLower Price Target$0.39 -> $0.34N/AView Rating Details
6/29/2016Noble FinancialDowngradeBuy -> HoldN/AView Rating Details
6/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
6/9/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
1/22/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$4.00N/AView Rating Details
12/8/2015Cantor FitzgeraldUpgradeSell -> Hold$2.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Galena Biopharma (NASDAQ:GALE)
Earnings by Quarter for Galena Biopharma (NASDAQ:GALE)
Earnings History by Quarter for Galena Biopharma (NASDAQ GALE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.15)($0.16)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.22)($0.09)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.05)($0.02)ViewListenView Earnings Details
8/9/2016Q216($0.06)$0.05ViewN/AView Earnings Details
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details
8/6/2015Q215($0.09)($0.07)$3.54 million$3.38 millionViewN/AView Earnings Details
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details
3/5/2015Q414($0.12)($0.09)$2.58 million$3.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.13)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details
5/6/2014Q1($0.10)($0.10)$2.09 million$2.17 millionViewN/AView Earnings Details
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Galena Biopharma (NASDAQ:GALE)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.98)($0.98)($0.98)
Q2 20171($0.94)($0.94)($0.94)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)


Dividend History for Galena Biopharma (NASDAQ:GALE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Galena Biopharma (NASDAQ:GALE)
Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 20.50%
Insider Trades by Quarter for Galena Biopharma (NASDAQ:GALE)
Institutional Ownership by Quarter for Galena Biopharma (NASDAQ:GALE)
Insider Trades by Quarter for Galena Biopharma (NASDAQ:GALE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017Rudolph NisiDirectorSell500$0.55$275.00View SEC Filing  
2/8/2017Hudson Bay Capital ManagementMajor ShareholderSell2,363,441$0.84$1,985,290.44View SEC Filing  
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Galena Biopharma (NASDAQ:GALE)
Latest Headlines for Galena Biopharma (NASDAQ:GALE)
DateHeadline logoHow Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio? - Yahoo Finance - September 21 at 12:55 AM logoHow Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio? - September 20 at 7:54 PM logoStock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health - September 18 at 6:31 PM logoForm 425 Galena Biopharma, Inc. Filed by: Galena Biopharma, Inc. - - September 15 at 12:35 AM logoGalena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership - GlobeNewswire (press release) - September 12 at 12:28 AM logoBRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership - September 11 at 7:26 PM logoGalena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership - September 11 at 7:26 PM
News IconUPDATE 1-Galena settles US kickback charges related to opioid drug - Business Insider - September 9 at 6:24 PM logoUPDATE 1-Galena settles US kickback charges related to opioid drug - Reuters - September 9 at 5:35 AM logoBRIEF-U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claims - September 8 at 7:23 PM logoGalena settles U.S. kickback charges related to opioid drug - September 8 at 7:23 PM logoHead-To-Head Analysis: Eyegate Pharmaceuticals (EYEG) & Galena Biopharma (GALE) - September 2 at 2:26 AM logoGalena Biopharma, Inc. (GALE) Expected to Post Earnings of -$0.15 Per Share - August 23 at 10:20 PM logoGalena Biopharma Inc (GALE) Announces Earnings Results - August 15 at 1:54 PM logoEarnings Reaction History: Galena Biopharma, Inc., 80.0% Follow-Through Indicator, 5.6% Sensitive - Nasdaq - August 14 at 7:14 PM logoGalena Biopharma Reports Second Quarter 2017 Financial Results - August 14 at 7:14 PM logoGalena Biopharma reports 2Q loss - August 14 at 7:14 PM logoGalena Biopharma (NASDAQ:GALE) versus Neos Therapeutics (NEOS) Critical Survey - August 11 at 10:52 PM logoThe Rosen Law Firm, P.A. Announces Proposed Settlement with Remaining Defendants in Galena Biopharmaceutical Securities Litigation - August 11 at 7:21 PM logoGalena Biopharma (GALE) Discusses Galena Biopharma and SELLAS Life Sciences Group Merger Call (Transcript) - August 11 at 7:21 PM logoMaxim Group Reaffirms Hold Rating for Galena Biopharma, Inc. (NASDAQ:GALE) - August 9 at 6:46 PM logoSELLAS Life Sciences to merge with Galena in all-stock deal - Seeking Alpha - August 9 at 4:40 AM logoGalena Biopharma Enters into Merger Agreement with SELLAS Life ... - GlobeNewswire (press release) - August 9 at 4:40 AM logoGalena Biopharma (GALE) to Merge with SELLAS Life Sciences Group - August 8 at 11:37 PM logoBRIEF-Galena Biopharma enters into merger agreement with Sellas Life Sciences Group - August 8 at 11:37 PM logoGalena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group - August 8 at 6:36 PM logoZacks: Brokerages Expect Galena Biopharma, Inc. (NASDAQ:GALE) to Announce -$0.15 EPS - July 14 at 12:33 PM logoGalena Biopharma Provides Corporate Update - GlobeNewswire (press release) - July 12 at 7:36 PM logoGalena Biopharma Provides Corporate Update - July 12 at 7:36 PM logoGalena Biopharma (GALE) & Apricus Biosciences (APRI) Head-To-Head Review - July 1 at 10:10 AM logo-$0.15 Earnings Per Share Expected for Galena Biopharma, Inc. (GALE) This Quarter - June 20 at 10:30 AM logoGalena Biopharma, Inc. (GALE) Receives Consensus Rating of "Hold" from Brokerages - June 16 at 1:08 PM logoBreakfast Technical Briefing on Biotech Stocks -- CEL-SCI, Amicus Therapeutics, Galena Biopharma, and Cleveland ... - PR Newswire (press release) - June 12 at 6:12 PM logoBRIEF-Galena Biopharma says received a notice of termination of BVI license agreement from BVI - Reuters - June 7 at 9:54 PM logoGalena Biopharma Inc (GALE) Lowered to Strong Sell at ValuEngine - June 4 at 3:34 PM logoShort Interest in Galena Biopharma Inc (GALE) Declines By 1.6% - May 27 at 4:26 PM logoZacks: Brokerages Anticipate Galena Biopharma Inc (GALE) to Post -$0.15 EPS - May 25 at 7:32 AM logoGalena Biopharma Inc (GALE) Receives Consensus Rating of "Hold" from Analysts - May 22 at 12:24 PM logoGalena Biopharma Inc (GALE) Lowered to "Hold" at Zacks Investment Research - May 16 at 10:40 PM logoAbbVie and J&J Present Positive Imbruvica Leukemia Data - May 15 at 11:24 AM logoGalena Biopharma reaches $7.5 million accord in U.S. opioid probe - May 12 at 4:00 AM logoGalena Biopharma Inc (GALE) Posts Earnings Results, Beats Estimates By $0.13 EPS - May 11 at 9:00 PM logoBRIEF-Galena Biopharma Q1 loss per share $0.45 - May 11 at 3:32 AM logoGalena Biopharma reports 1Q loss - May 10 at 10:30 PM logoGalena Biopharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 10 at 5:29 PM logoGalena Biopharma Reports First Quarter 2017 Financial Results - May 10 at 5:29 PM logoJuno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss - May 5 at 5:32 PM logo Brokerages Anticipate Galena Biopharma Inc (GALE) Will Post Earnings of -$0.22 Per Share - May 2 at 10:52 AM logoGalena Biopharma (GALE) Receives Daily Media Sentiment Rating of -0.15 - April 29 at 8:18 AM logoGalena Biopharma Inc (GALE) Sees Significant Increase in Short Interest - April 29 at 7:20 AM



Galena Biopharma (GALE) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff